Astellas Appoints New Vice President, Americas Finance
Astellas promoted Anthony Fiordaliso, MBA, CPA to Vice President, Americas Finance after previously serving as the company’s Executive Director, Commercial Finance. Fiordaliso has contributed to financials in Astellas since 2010, preparing him for overseeing financial planning and analysis, revenue forecasting and recognition, collaboration finance, and expense management for Astellas Americas, which includes United States, Canada, Brazil, Colombia, and the rest of Latin America.
Stephen Knowles, Senior Vice President, Finance and Information Technology, comments, “Tony’s depth and breadth of knowledge and experience in finance related to the pharmaceutical industry positions him well for his new role.”
Zimmer Bioment Taps Bryan C. Hanson, Formerly of Medtronic
Bryan C. Hanson is now Zimmer Biomet’s new President and Chief Executive Officer after serving as a member of the Executive Committee and Executive Vice President and President of rival Medtronic’s Minimally Invasive Therapies Group. Larry C. Glasscock, Chairman of the Zimmer Biomet Board of Directors, said in a statement, “Bryan is a proven executive with a track record of successfully leading, growing, and transforming global medical device businesses to achieve higher levels of innovation, commercial success, and profitability. We look forward to working closely with Bryan to further leverage our leading portfolio of technologies, solutions, and personalized services to enhance stockholder value.”
Damien McDevitt, PhD joins ACADIA Pharmaceuticals after 20 years with GlaxoSmithKline. He most recently served as GSK’s VP, Head of Business Development for R&D Extended Therapy Areas. He will now help expand ACADIA’s portfolio as Senior Vice President of Corporate Development.
The drug maker focused on cancer and rare genetic disease has made an addition to its Board of Directors with Jackie Fouse, PhD as it prepares to launch its first precision medicine. Fouse has years of experience with this type of launch, having spent eighteen years at Celgene as CFO and most recently, President and COO.
Amneal Pharmaceuticals LLC and Impax Laboratories, Inc.
Needing a strong leader during their merger, generics companies Amneal Pharmaceuticals and Impax Laboratories named Robert Stewart President. Stewart leaves his position as COO at Allergan, where he has worked in leadership positions since 2009. He brings 22 years of experience in global brand and generic pharma management to the combined company, and will guide the pre-integration planning work.
Apellis Pharmaceuticals appointed Timothy Sullivan to the position of Chief Financial Officer. Sullivan was a Partner at AJU IB Investment, where he gained experience leading the firm’s life sciences investments. He will lead the development of the biopharmaceutical company’s financing strategy in 2018.
Catalyst Biosciences appointed Edward Williams as a member of its Board of Directors where he will help drive growth in the hemophilia field. Previously, Williams was Senior Vice President of Biopharmaceuticals at Novo Nordisk, where he was responsible for the general management of all aspects of the biotechnology business for the U.S. in three therapeutic areas.
Agency veteran, Doug Dome, is named Fusion92’s President. Dome previously founded Core7, a startup that leverages artificial intelligence and machine learning to create industry-specific master algorithms to engineer the optimization of integrated marketing communications ecosystems. Dome previously served in numerous senior agency leadership roles with iconic brands.
GCI Health moved West Coast Lead, Edie DeVine, to the newly created role of U.S. Director of Medical and Health Technology. She will now be responsible for growth in the firm’s medical device and health IT client work sector.
Intouch added two management team additions, promoting both Alex Buchart and Alexis Iacona from Marketing Coordinators to Account Managers. Buchart joined the Intouch family in 2015 and her success in that role prepared her to manage multiple client accounts and introduce clients to new business opportunities as well as overseeing many of Intouch’s internal processes.Serving with Intouch since 2016, Iacona manages three high-level client accounts while assisting with higher level strategic initiatives, including new business development and brand planning.
Novartis announced that Bruno Strigini, CEO Novartis Oncology, will be retiring for personal reasons after holding his position since 2014. He managed the integration of GlaxoSmithKline’s oncology programs and helped the company launch top CAR-T treatment option, Kymriah.
The clinical-stage pharmaceutical company announced that Jacob Harel, an industry veteran with more than 30 years experience, has been appointed Chairman of the Board of Directors. He previously founded Harel Group, a business development advisory firm in the global pharmaceutical industry, while spending 27 years ascending the ranks at Merck & Co.
Alan Wexler, who has served as Co-chief Executive Publicis.Sapient and Chief Executive of SapientRazorfish, will now take over as Chief Executive of Publicis.Sapient following Chip Register’s retirement. He will be responsible for speeding up the integration of digital business transformation at the core of the group. Wexler had led SapientNitro America during the past six years and guided SapientRazorfish’s digital transformation. He also founded and operated a management and technology consulting firm.
The healthcare information group has named Matthew Kirby Business Development Director to lead multichannel marketing and NHS service redesign. Kirby comes from Janssen Pharmaceuticals, where he served most recently as Regional Business Manager in the U.K. for its diabetes sales team.